指南与共识免疫规划

建议常规免疫前后男孩四价人乳头瘤病毒疫苗系列完成情况

Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization.
指南 / 共识 · Vaccine · 2017-01-13

研究基于Kaiser Permanente南加州健康计划电子病历,分析9-17岁男孩在2009-2013年间不同4vHPV启动时期(许可及允许使用、增加肛门癌适应证、ACIP常规推荐)的系列完成情况。80800名启动4vHPV的男孩中,24.3%在12个月内完成系列,各队列间差异极小。完成率随启动年龄增大而降低,有初级保健提供者、接种流感疫苗者及亚裔/太平洋岛民完成率较高,非西班牙裔黑人和西班牙裔较低。

要点

  • 80800名启动4vHPV的男孩中仅24.3%在12个月内完成系列,各时期队列间差异极小。
  • 13-17岁启动者完成率低于11-12岁者(AHR=0.85,95%CI=0.80,0.89)。
  • 有初级保健提供者(AHR=1.28)、接种流感疫苗(AHR=1.50)者完成率较高。

核心结论

  • 尽管ACIP已推荐男性常规使用4vHPV,系列完成率仍低。
  • 11-12岁启动4vHPV及确定负责青少年健康照护的提供者可能提高系列完成率。
  • 鉴于男性HPV相关癌症发病率快速上升,识别提高HPV疫苗系列完成的措施很重要,尤其针对非西班牙裔黑人和西班牙裔男性。

研究设计与样本

  • 研究为基于Kaiser Permanente南加州健康计划电子病历的队列分析,纳入9-17岁启动4vHPV的男孩。
  • 按4vHPV启动日期分为3个队列:许可及ACIP允许使用(2009-2010年)、增加肛门癌适应证(2010-2011年)、ACIP常规推荐(2011-2013年)。
  • 采用边际Cox比例风险模型估计患者和提供者特征与接种之间的调整风险比(AHR)。

主要发现

  • 80800名启动4vHPV的男孩中,24.3%在12个月内完成系列,各队列间差异极小。
  • 完成率随启动年龄增大而降低:13-17岁 vs 11-12岁 AHR=0.85(95%CI=0.80,0.89)。
  • 有初级保健提供者者完成率较高:AHR=1.28(95%CI=1.17,1.41)。
  • 接种流感疫苗者完成率较高:AHR=1.50(95%CI=1.43,1.57)。
  • 亚裔/太平洋岛民完成率较高:AHR=1.07(95%CI=1.00,1.15);非西班牙裔黑人AHR=0.72(95%CI=0.65,0.80)、西班牙裔AHR=0.86(95%CI=0.81,0.90),均以非西班牙裔白人为参照。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the incidence of HPV-attributable cancers in males is rapidly increasing, HPV vaccine uptake in males remains poor. While quadrivalent human papillomavirus vaccine (4vHPV) series initiation in males increased following the Advisory Committee Immunization Practices (ACIP) male routine use recommendation, its impact on 4vHPV series completion in males at ACIP-recommended intervals has not been evaluated in large male cohorts. We examined trends and correlates of 4vHPV completion since licensure in males in a large cohort of insured boys before and after the ACIP routine use recommendation. METHODS: We grouped data from electronic medical records of males aged 9-17years from Kaiser Permanente Southern California health plan who initiated 4vHPV into 3 cohorts by 4vHPV initiation date: licensure and ACIP permissive use: 2009-2010; addition of anal cancer indication: 2010-2011; ACIP routine use: 2011-2013. We estimated adjusted hazard ratios (AHRs) between patient and provider characteristics and vaccination using Marginal Cox proportional hazards models. RESULTS: Of 80,800 boys initiating 4vHPV, 24.3% completed the series within 12months with minimal differences across cohorts. Completion decreased with increasing age at initiation (13-17vs. 11-12year olds: AHR=0.85; 95% confidence interval [CI]=0.80, 0.89) and was greater among patients with a primary care provider (AHR=1.28, 95%CI=1.17, 1.41), influenza vaccine recipients (AHR=1.50, 95% CI=1.43, 1.57), and Asian/Pacific Islanders (AHR=1.07, 95% CI=1.00, 1.15), and lower among non-Hispanic Blacks (AHR=0.72, 95% CI=0.65, 0.80) and Hispanics (AHR=0.86, 95% CI=0.81, 0.90) compared to non-Hispanic Whites. CONCLUSIONS: Despite the ACIP routine use recommendation in males, 4vHPV series completion remained low. 4vHPV initiation at 11-12years and identification of a provider responsible for the adolescents' health care may increase 4vHPV series completion. Given the rapidly increasing incidence of HPV-related cancers in males, it is important to identify measures to increase HPV vaccine series completion, particularly among non-Hispanic Black and Hispanic males.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ackerson B, Hechter R, Sidell M, et al. Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization. Vaccine. 2017. PMID: 28094077. doi:10.1016/j.vaccine.2017.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。